Companies in #Antibody-Drug Conjugates (ADCs)

MacroGenics is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-based therapeutics for cancer. Its proprietary DART and TRIDENT bispecific platforms enable multi-specific targeting, and the company has one approved HER2-targeted breast cancer drug, Margenza (margetuximab-cmkb).

Tubulis is a biotechnology company developing a new generation of antibody-drug conjugates (ADCs) for the treatment of cancer. Its proprietary platforms — Tub-tag, P5 conjugation, and Topoisomerase-I inhibitor payloads — enable the design of highly stable, targeted ADCs with improved therapeutic index. In May 2026, Gilead Sciences completed the acquisition of Tubulis for up to $5 billion ($3.15B cash upfront + $1.85B milestones).